Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Some activists are beginning to complain about Gilead's decision to charge so much for sofosbuvir.

Published
06 January 2014
From
NPR (blog)
Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Gilead Sciences (GILD) received approval earlier this month for what may well be one of the most successful drugs to be approved in years-- Sovaldi, its novel hepatitis drug. Sovaldi, which some analysts say can actually cure some hepatitis cases, is expected to be a blockbuster for the company and could see sales surpassing $8 billion annually by 2018. On the heels of the approval, Gilead announced that it will now seek U.S. approval for a combination of Sovaldi and its newest hepatitis drug -- ledipasvir -- in the first quarter of 2014. The combination of these two drugs could be a "one-two knockout"… not just of the disease, but of the competition as well.

Published
03 January 2014
From
Seeking Alpha
Stellar hepatitis C data puts Gilead farther ahead of pack

Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline.

Published
24 December 2013
From
Reuters
Life-saving hepatitis C drug approved, but cost is high

Following approvals in the US and Europe this month of a new drug to treat hepatitis C, activists are pushing for the medication to be made available in poor countries.

Published
24 December 2013
From
IRIN Plus News
Egyptians hold their breath as new Hepatitis C drugs promise cure

In Egypt, millions suffering from genotype 4 Hepatitis C count the days until the official approval of new breakthrough drugs, hoping for affordable prices.

Published
24 December 2013
From
Ahram Online
Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks

A two-drug combination of sofosbuvir and ledipasvir cured 94% of previously untreated patients with genotype 1 hepatitis C infection after eight weeks, without the need for ribavirin,

Published
18 December 2013
By
Keith Alcorn
Gilead to seek okay for combo hepatitis C pill in first quarter

Gilead Sciences Inc, based on favorable new clinical trial data, said it will seek U.S. approval in the first quarter of 2014 for a once-daily tablet containing two new treatments for hepatitis C.

Published
18 December 2013
From
Reuters
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

High Cure Rates Observed with Single Tablet Regimen May Eliminate Interferon and Ribavirin from HCV Therapy for Genotype 1 Patients; U.S. NDA Submission Planned for Q1 2014.

Published
18 December 2013
From
Gilead press release
How patent rules could keep new hepatitis C drug from saving 'millions of lives'

While affordable medicine advocates in India prepare to fight the patenting of a new hepatitis C drug, the US works to strengthen pharmaceutical patents through an international trade deal.

Published
18 December 2013
From
Global Post
An interview with Professor Jean-Michel Pawlotsky on how the treatment of HCV infection will change in the near future

Professor Jean-Michel Pawlotsky, Director of the French National Reference Center for Viral Hepatitis B, C and delta, comments on recent developments in hepatitis C treatment - and the price barriers to access in Europe and in low and middle-income countries.

Published
17 December 2013
From
Hepatitis B & C Public Policy Association

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.